FDA To Hold Financial Transparency Meeting For User Fee Programs

FDA is planning to hold a public meeting on financial transparency and efficiency of the prescription drug, generic drug and biosimilar user fee programs in June, and is soliciting public comments ahead of the event on topics addressed in the programs’ commitment letters. The notice was posted in the Federal Register Tuesday (April 9). The meeting will be held virtually on June 6. “This meeting will provide FDA with the opportunity to update interested public stakeholders on topics related...